Developing science,
delivering therapies

Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more

News

Second-generation Live Biotherapeutic Identified and Mechanistic Data on MRx0518 and MRx1299 Presented
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its lead Live Biotherapeutic candidate for asthma, MRx-4DP0004.
4D pharma plc (AIM: DDDD) today announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn’s disease will be presented by the Lead Investigator, Richard Hansen, Consultant Paediatric Gastroenterologist, Royal Hospital for Children, Glasgow will also give an oral presentation on this data at the 52nd Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) in Glasgow, UK, on 7 June 2019.

BACK TO TOP